Diabetic ulcers: shockwaves versus hyperbaric oxygen · Randomized trial · 2011
How does shockwave compare with hyperbaric oxygen for diabetic foot ulcers?
In this trial, ulcers closed completely in 24 of 44 feet after six shockwave sessions, compared with 10 of 40 feet after a course of hyperbaric oxygen (breathing oxygen in a pressure chamber). Blood flow in the foot also rose after shockwave.
- people with diabetic foot ulcers
- 88
- shockwave sessions over 3 weeks
- 6
- hyperbaric oxygen sessions in the other group
- 40
Good to know: Results were counted per foot (84 feet in 77 people), and a few of the report's counts don't match its percentages.
Wang CJ, Wu RW, Yang YJ Diabetes Res Clin Pract, 2011 · Read the paper ↗
How this study worked
The treatment
Shockwave
Shockwave, twice a week for 3 weeks
- Pulses
- 500 per session · at least; more for bigger wounds (8 per cm² of wound plus a 1 cm border)
- Strength
- 0.23mJ/mm² setting E2, as printed · 4 per second
- Numbing
- None
- Device
- dermaPACE
- Everyone also got
- Pressure relief for the foot, saline cleaning, silver sulfadiazine cream and antibiotics when needed
Compared with: Hyperbaric oxygen: 40 sessions of 90 minutes breathing oxygen in a pressure chamber, with the same wound care
Settings are what each study used, not a prescription.
Who took part
88 people with long-standing diabetic foot ulcers: 43 had shockwave and 45 hyperbaric oxygen; 77 people (84 feet) were analysed.
hollow squares: no final score
Side effects
No complications from shockwave were reported. Four people in the oxygen group had ear or sinus pain from the pressure, which settled. Two people in the shockwave group died of causes judged unrelated.
All the numbers and the full appraisal
What the full paper reports.
88 allocated patients, 43 ESWT/45 HBOT; 77 patients with 84 feet analyzed after 4/7 losses, respectively.
Participant counts; outcome-specific denominators remain in each panel.
Participant counts; outcome-specific denominators remain in each panel.
Reported complete closure, conflicting percentage1 reported outcome
Reported complete closure, conflicting percentage
Reported complete closure, conflicting percentage affected feet
Between reported groups
Source-reported comparison
Complete closure: Table 3 prints 57% (24 of 44 feet) with ESWT versus 25% (10 of 40 feet) with HBOT. Numbers are as printed: 24/44 is 54.5%, not 57% (25/44 would give 57%), and the ESWT first-course categories add up to 43 of 44 feet. Foot denominators, not participants.
Analysis details and source
Complete closure: Table 3 prints 57% (24 of 44 feet) with ESWT versus 25% (10 of 40 feet) with HBOT. Numbers are as printed: 24/44 is 54.5%, not 57% (25/44 would give 57%), and the ESWT first-course categories add up to 43 of 44 feet. Foot denominators, not participants.
At least 50% improvement1 reported outcome
At least 50% improvement
At least 50% improvement affected feet
Between reported groups
Source-reported comparison
Improvement: 14/44 ESWT feet versus 6/40 HBOT feet. Not statistically significant; distinct from complete closure.
Analysis details and source
Improvement: 14/44 ESWT feet versus 6/40 HBOT feet. Not statistically significant; distinct from complete closure.
Complete closure after selected second course1 reported outcome
Complete closure after selected second course
Complete closure after selected second course affected feet
Between reported groups
Source-reported comparison
Second-course closure: 7/14 selected ESWT ulcers versus 1/17 selected HBOT ulcers. Selected responding but unhealed ulcers; no new randomization.
Analysis details and source
Second-course closure: 7/14 selected ESWT ulcers versus 1/17 selected HBOT ulcers. Selected responding but unhealed ulcers; no new randomization.
Doppler perfusion1 reported outcome
Doppler perfusion
Doppler perfusion arbitrary perfusion units; feet
Table 4 reports ESWT perfusion 0.48 (range 0.32–0.64) before and 0.61 (0.40–0.79) after treatment, within-group p<.001; HBOT 0.59 (0.50–0.63) and 0.50 (0.11–0.53), p=.916. Between-group p=.245 before and p=.002 after. These are source-reported values in arbitrary perfusion units for 44 versus 40 feet, not independent people; ranges are not standard deviations.
Analysis details and source
Table 4 reports ESWT perfusion 0.48 (range 0.32–0.64) before and 0.61 (0.40–0.79) after treatment, within-group p<.001; HBOT 0.59 (0.50–0.63) and 0.50 (0.11–0.53), p=.916. Between-group p=.245 before and p=.002 after. These are source-reported values in arbitrary perfusion units for 44 versus 40 feet, not independent people; ranges are not standard deviations.
Unchanged and partial responses1 reported outcome
Unchanged and partial responses
Unchanged and partial responses affected feet
After the first course, 5/44 ESWT feet and 24/40 HBOT feet were unchanged (p<.001); none worsened. In the selected second-course subgroups, ≥50% improvement occurred in 6/14 versus 8/17 feet (p=.815), and no change in 1/14 versus 8/17 (p=.015); none worsened. The second course was discretionary, not a new randomized comparison.
Analysis details and source
After the first course, 5/44 ESWT feet and 24/40 HBOT feet were unchanged (p<.001); none worsened. In the selected second-course subgroups, ≥50% improvement occurred in 6/14 versus 8/17 feet (p=.815), and no change in 1/14 versus 8/17 (p=.015); none worsened. The second course was discretionary, not a new randomized comparison.
How treatment was delivered
dermaPACE, E2 printed 0.23 mJ/mm², 4 Hz, impulses=area expanded 1 cm× 8, minimum 500; twice weekly× 3 weeks, no anesthesia. HBOT 2.5 ATA× 90 min× 40; offloading, saline, silver sulfadiazine±antibiotics.
Four HBOT patients had middle-ear barotrauma/sinus pain resolving with decompression; no systemic/local ESWT complication reported. Two ESWT-arm deaths were classified unrelated and excluded.
Open-label, predictable odd/even assignment; 11 exclusions and foot-level analysis without clustering adjustment. Table 3 ESWT categories sum 43, not 44, and 24/44 is not 57%. Second courses were clinician-selected, not rerandomized. Sanuwave supplied device/applicators; Wang advisory relationship disclosed. Funding: Chang Gung research grant CMRPG880221.
Findings checked against the full source by a separate automated reviewer.
Limitations noted by the reviewers
- Open-label, predictable odd/even assignment; 11 exclusions and foot-level analysis without clustering adjustment. Table 3 ESWT categories sum 43, not 44, and 24/44 is not 57%. Second courses were clinician-selected, not rerandomized. Sanuwave supplied device/applicators; Wang advisory relationship disclosed. Funding: Chang Gung research grant CMRPG880221.
Source-linked critical reading
Randomized trials
Technical source record
Full source read: body, methods, results, all tables and figure captions, discussion and disclosures. The article lists no supplementary material.
The report favored shockwaves, but inconsistent healing counts and study design mean the size of the advantage remains uncertain.
How do shockwave treatment and hyperbaric oxygen compare for healing chronic diabetic foot ulcers?
Comparative trial assigning 88 patients by predictable odd/even numbers; 77 people with 84 feet entered the reported analysis. Allocation was described as randomized but concealment is doubtful.
88 allocated patients, 43 ESWT/45 HBOT; 77 patients with 84 feet analyzed after 4/7 losses, respectively.
Six ESWT sessions over 3 weeks, with offloading and local wound care.
Forty HBOT sessions, 2.5 ATA, 90 min, five per week; same wound care.
The extracted panels retain the original outcome units and assessment times. Table 3 reports 57% (24/44) completely healed after ESWT and 25% (10/40) after HBOT, p=.003; numerator and percentage conflict. ≥50% improvement 14/44 versus 6/40, p=.071; unchanged 5/44 versus 24/40. Perfusion post-treatment 0.61 versus 0.50, p=.002.
Table 3 reports 57% (24/44) completely healed after ESWT and 25% (10/40) after HBOT, p=.003; numerator and percentage conflict. ≥50% improvement 14/44 versus 6/40, p=.071; unchanged 5/44 versus 24/40. Perfusion post-treatment 0.61 versus 0.50, p=.002.
Four HBOT patients had middle-ear barotrauma/sinus pain resolving with decompression; no systemic/local ESWT complication reported. Two ESWT-arm deaths were classified unrelated and excluded.
Open-label, predictable odd/even assignment; 11 exclusions and foot-level analysis without clustering adjustment. Table 3 ESWT categories sum 43, not 44, and 24/44 is not 57%. Second courses were clinician-selected, not rerandomized. Sanuwave supplied device/applicators; Wang advisory relationship disclosed. Funding: Chang Gung research grant CMRPG880221.
Suggestive comparison with HBOT, but source discrepancies and attrition prevent a clean precision estimate or general claim of superiority.
Use concealed randomization, retain deaths and withdrawals in patient accounting, reconcile foot-level closure counts and prespecify any second treatment course with a separate randomized comparison.
Read the original article.
Treatment of diabetic foot ulcers: A comparative study of extracorporeal shockwave therapy and hyperbaric oxygen therapy
Wang CJ, Wu RW, Yang YJ. · Diabetes Res Clin Pract · 2011
Open the publication record or available full-text files.
Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →